Highlights from the PER® CME activity "Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, PhD; and Sara Nunnery, MD, MSCI, review pivotal clinical trials investigating novel endocrine therapies and targeted combination regimens for hormone receptor-positive, HER2-negative metastatic breast cancer, and discuss strategies for selecting the optimal treatment approach for individual patients.

Earn CME credit by completing the full accredited activity (available through April 23, 2027):
https://www.gotoper.com/courses/medical-crossfire-expanding-options-evolving-challenges-in-advanced-hrher2-breast-cancer-how-experts-apply-the-latest-data-vv3z

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc; Genentech, Inc; Lilly; and Stemline Therapeutics.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

S17 Ep5: Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

OncLive® On Air

S17 Ep5: Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data